Autosomal recessive chronic granulomatous disease gene therapy - Orchard Therapeutics
Alternative Names: AR-CGD gene therapy - Orchard TherapeuticsLatest Information Update: 02 Feb 2024
At a glance
- Originator Orchard Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Neutrophil cytosolic factor 1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Chronic granulomatous disease
Most Recent Events
- 24 Jan 2024 Orchard Therapeutics has been acquired by Kyowa Kirin